AU2021317376A1 - Bifunctional molecules targeting PD-l1 and TGF-beta - Google Patents

Bifunctional molecules targeting PD-l1 and TGF-beta Download PDF

Info

Publication number
AU2021317376A1
AU2021317376A1 AU2021317376A AU2021317376A AU2021317376A1 AU 2021317376 A1 AU2021317376 A1 AU 2021317376A1 AU 2021317376 A AU2021317376 A AU 2021317376A AU 2021317376 A AU2021317376 A AU 2021317376A AU 2021317376 A1 AU2021317376 A1 AU 2021317376A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
antibody
fragment
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021317376A
Other languages
English (en)
Inventor
Wenci GONG
Yiwei TOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lepu Biopharma Co Ltd
Original Assignee
Lepu Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lepu Biopharma Co Ltd filed Critical Lepu Biopharma Co Ltd
Publication of AU2021317376A1 publication Critical patent/AU2021317376A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021317376A 2020-07-28 2021-07-27 Bifunctional molecules targeting PD-l1 and TGF-beta Abandoned AU2021317376A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/105286 2020-07-28
CN2020105286 2020-07-28
CNPCT/CN2021/098476 2021-06-04
CN2021098476 2021-06-04
PCT/CN2021/108643 WO2022022503A1 (en) 2020-07-28 2021-07-27 Bifunctional molecules targeting pd-l1 and tgf-beta

Publications (1)

Publication Number Publication Date
AU2021317376A1 true AU2021317376A1 (en) 2023-02-23

Family

ID=80037607

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021317376A Abandoned AU2021317376A1 (en) 2020-07-28 2021-07-27 Bifunctional molecules targeting PD-l1 and TGF-beta

Country Status (9)

Country Link
US (1) US20230287125A1 (https=)
EP (1) EP4188950A4 (https=)
JP (3) JP2023540436A (https=)
KR (1) KR20230050356A (https=)
CN (4) CN121319180A (https=)
AU (1) AU2021317376A1 (https=)
IL (1) IL299966A (https=)
PH (1) PH12023550193A1 (https=)
WO (1) WO2022022503A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026508210A (ja) * 2023-02-20 2026-03-10 中山康方生物医▲藥▼有限公司 ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9676863B2 (en) * 2014-02-10 2017-06-13 Merck Patent Gmbh Targeted TGFβ inhibitors
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN108779180B (zh) * 2016-03-23 2020-10-16 迈博斯生物医药(苏州)有限公司 新型抗-pd-l1抗体
EP3369745B1 (en) * 2016-08-04 2021-09-29 Innovent Biologics (Suzhou) Co., Ltd. Anti-pd-l1 nanobody and use thereof
EP3551659A1 (en) * 2016-12-08 2019-10-16 Eli Lilly and Company Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
AU2018264455B2 (en) * 2017-05-12 2024-12-12 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing TGF-beta receptor and medicinal uses thereof
CN109575140B (zh) * 2017-09-29 2021-02-23 北京比洋生物技术有限公司 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途
EP3470429A1 (en) * 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
CN109721657B (zh) * 2017-10-27 2021-11-02 北京比洋生物技术有限公司 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途
JP7348899B2 (ja) * 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
WO2019185029A1 (en) * 2018-03-29 2019-10-03 I-Mab Anti-pd-l1 antibodies and uses thereof
BR112021003093A2 (pt) * 2018-08-22 2021-05-11 Merck Patent Gmbh tratamento de câncer de mama triplo negativo que visa a inibição de tgf-beta
US12559539B2 (en) * 2018-11-09 2026-02-24 Jiangsu Hengrui Medicine Co., Ltd. TGF-beta receptor fusion protein pharmaceutical composition and use thereof
US10851157B2 (en) * 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
US11028174B1 (en) * 2020-07-28 2021-06-08 Lepu Biopharma Co., Ltd. Bifunctional molecules targeting PD-L1 and TGF-β
CN112940134B (zh) * 2021-05-11 2021-09-03 正大天晴药业集团南京顺欣制药有限公司 针对PD-1和TGF-β的双功能蛋白

Also Published As

Publication number Publication date
CN119462927B (zh) 2025-07-29
EP4188950A1 (en) 2023-06-07
PH12023550193A1 (en) 2024-06-24
WO2022022503A1 (en) 2022-02-03
JP2023540436A (ja) 2023-09-25
JP2025010203A (ja) 2025-01-20
IL299966A (en) 2023-03-01
KR20230050356A (ko) 2023-04-14
CN116348493B (zh) 2025-10-17
CN119409832B (zh) 2025-08-01
EP4188950A4 (en) 2025-01-22
CN121319180A (zh) 2026-01-13
US20230287125A1 (en) 2023-09-14
JP2026015500A (ja) 2026-01-29
CN116348493A (zh) 2023-06-27
JP7846734B2 (ja) 2026-04-15
CN119462927A (zh) 2025-02-18
CN119409832A (zh) 2025-02-11

Similar Documents

Publication Publication Date Title
US11634490B2 (en) Blocking antibodies against CD47 and methods of use thereof
US11873342B2 (en) Anti-CCR8 monoclonal antibodies and uses thereof
US11261259B2 (en) Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof
KR102514317B1 (ko) 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
US11028174B1 (en) Bifunctional molecules targeting PD-L1 and TGF-β
US11497769B2 (en) Anti-CD19 antibodies
US11028172B1 (en) Anti-TIGIT antibodies and uses thereof
TWI821699B (zh) 抗b7h4抗體及其雙抗和應用
CN115038720B (zh) 抗gprc5d单克隆抗体及其用途
IL276447B2 (en) Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
US20250154248A1 (en) Anti-slc34a2 monoclonal antibodies and uses thereof
JP2026015500A (ja) Ｐｄ－ｌ１およびｔｇｆ－βを標的とする二機能性分子
HK40088153A (zh) 靶向PD-L1和TGF-β的双功能分子
HK40126806A (zh) 抗slc34a2单克隆抗体及其用途
HK40100726A (zh) 抗tigit抗体及其用途
HK40057849B (zh) 抗紧密连接蛋白18.2和抗4-1bb双特异性抗体及其用途
KR20210093270A (ko) 인간화 항-SIRPα 항체
HK40046552B (zh) 对cd3特异性的抗体及其用途

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application